Adaptive Biotechnologies Corp — Director's Dealing 2020

May 19, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Adaptive Biotechnologies Corp (ADPT)
CIK: 0001478320
Period of Report: 2020-05-14

Reporting Person: ROBINS HARLAN S (Chief Scientific Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-05-14	Common Stock	M	31200	$6.32	Acquired	101879	Direct
2020-05-14	Common Stock	S	3200	$34.26	Disposed	98679	Direct
2020-05-14	Common Stock	S	28000	$35.44	Disposed	70679	Direct
2020-05-15	Common Stock	M	35400	$6.32	Acquired	106079	Direct
2020-05-15	Common Stock	S	100	$33.56	Disposed	105979	Direct
2020-05-15	Common Stock	S	400	$35.13	Disposed	105579	Direct
2020-05-15	Common Stock	S	5400	$36.34	Disposed	100179	Direct
2020-05-15	Common Stock	S	22342	$37.53	Disposed	77837	Direct
2020-05-15	Common Stock	S	7158	$38.11	Disposed	70679	Direct
2020-05-18	Common Stock	M	11100	$6.32	Acquired	81779	Direct
2020-05-18	Common Stock	S	600	$38.67	Disposed	81179	Direct
2020-05-18	Common Stock	S	10500	$39.36	Disposed	70679	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-05-14	Stock Option (Right to Buy)	$6.32	M	31200	Disposed	2025-06-09	Common Stock (31200)	Direct
2020-05-15	Stock Option (Right to Buy)	$6.32	M	35400	Disposed	2025-06-09	Common Stock (35400)	Direct
2020-05-18	Stock Option (Right to Buy)	$6.32	M	11100	Disposed	2025-06-09	Common Stock (11100)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	300000	Indirect
Common Stock	500000	Indirect

Footnotes

F1: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2019.

F2: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $33.91 to 34.90, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

F3: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $34.92 to 35.91, inclusive.

F4: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $34.71 to 35.53, inclusive.

F5: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $35.80 to 36.72, inclusive.

F6: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $36.98 to 37.97, inclusive.

F7: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $37.98 to 38.26, inclusive.

F8: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $38.63 to 38.76, inclusive.

F9: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $38.91 to 39.89, inclusive.

F10: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

F11: The option is fully vested and exercisable.